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CASE1
LESSONS LEARNED: FROM COVERAGE WITH EVIDENCE
DEVELOPMENT FOR POSITRON EMISSION TOMOGRAPHY 
SCANS FOR ONCOLOGIC INDICATIONS
Whicher DM, Tunis S
Center for Medical Technology Policy, Baltimore, MD, USA
ORGANIZATION: The Centers for Medicare and Medicaid Services (CMS).
PROBLEM OR ISSUE ADDRESSED: In 2005, CMS issued a national coverage deter-
mination for Positron Emission Tomography (PET) for oncologic indications not previ-
ously covered by Medicare, which provided payment for PET scans for these indications 
only in the context of an approved prospective clinical trial designed to assess clinical 
utility of PET. CMS instated this policy option, referred to as ‘Coverage with Evidence 
Development’ (CED), due to the lack of evidence demonstrating the clinical effective-
ness of PET scans for patient management, which is necessary to determine whether 
PET scans are reasonable and necessary for the diagnosis, staging, re-staging, and 
monitoring of various cancer types. CED allowed CMS to guide evidence development 
while providing access to this potentially beneﬁ cial technology. GOALS: To determine 
whether PET imaging is clinically effective for previously uncovered oncologic indica-
tions. OUTCOMES ITEMS USED IN THE DECISION: The main outcomes were 
change in intended management strategy and whether the PET scan allowed physicians 
to avoid other tests or procedures. Based on these, Medicare’s Evidence Development
and Coverage Advisory Committee (MEDCAC) members had to decide how conﬁ dent 
they were that PET improves physician decision-making and clinical outcomes, and 
that the conclusions were generalizable to other cancers, to PET facilities in the general 
community, and to the Medicare population. IMPLEMENTATION STRATEGY: Since
CMS did not have the capacity to design and fund a study, the agency partnered with
the American College of Radiology and the Academy of Molecular Imaging. The study 
itself had to be implemented within a short time do to federal regulations. The registry 
began patient and physician registration in May of 2006. This design was chosen in
part because it balanced the desire for access to this service with the goal of generating 
evidence of reasonable quality that could be used by CMS to make a ﬁ nal coverage
determination. RESULTS: After the ﬁ rst year, most PET facilities in the United States
had signed up to participate in the registry and a huge nationwide sample of data had
been collected. The results from this data analysis demonstrate that physicians report 
a change in intended disease management strategy in about one out of every three cases 
and that when broken down by disease cancer type and indication, the ﬁ gure remains 
fairly constant (Hillner et al. 2008). This evidence was reviewed in August 2008 at a 
meeting of MEDCAC. Based on these results and the results of a health technology
assessment, MEDCAC members were asked to rate their conﬁ dence in the clinical
utility of PET and the generalizability of the conclusions. The ratings demonstrated
that MEDCAC members have limited conﬁ dence that PET improves clinical outcomes
based on the evidence. Members pointed out that although the results show that physi-
cians often change their intended management plan, there is no way to know if actual
management changed and even if it did, it is also not known whether these changes
actually lead to better patient outcomes. Still, on January 6, 2009, CMS issued a deci-
sion memo stating that there is now sufﬁ cient evidence showing that PET improves
health outcomes when used for the diagnosis and staging of all previously uncovered
cancer types, warranting coverage for these indications. However, CMS does not
believe that there is enough evidence demonstrating the clinical utility of PET for 
monitoring response to treatment and re-staging. Therefore, these indications will still 
only be covered through the CED policy, likely necessitating the development of a new
prospective study. LESSONS LEARNED: The case presented above not only demon-
strates that CED is operationally and technically possible while abiding to regulatory 
procedures, it also demonstrates CED can be used to help support research efforts 
designed to address questions of importance to health care decision-makers. In addi-
tion, as this is one of the ﬁ rst examples of Medicare taking advantage of CED, it also 
offers some lessons for the future. For instance, in order to streamline the process, it 
is necessary to identify a stable source of funding for these projects, to identify promis-
ing technologies which lack evidence of clinical effectiveness earlier in the development 
process, to reach a shared understanding among stakeholders of standards of evidence 
that are feasible and sufﬁ ciently robust for coverage decisions, and to reach a consensus
as to the most efﬁ cient methods for conducting real world trials. In the future, it would
be best if decisions of study design did not take place while Medicare was making a 
coverage determination and if private payers became involved in CED so a broader
range of patients could participate in the studies.
CASE2
TOWARDS AN INTEGRATED APPROACH TO THE ASSESSMENT
OF SURROGATE OUTCOME DATA
Platona A, Lopert R, Sansom L
Department of Health and Ageing, Canberra, ACT, Australia
ORGANIZATION: The Pharmaceutical Beneﬁ ts Advisory Committee (PBAC) is a
statutory independent expert committee which makes recommendations to the 
Australian Government on medicines to be listed on the national reimbursement
formulary (Pharmaceutical Beneﬁ ts Scheme). PROBLEM OR ISSUE ADDRESSED:
The proportion of regulatory and reimbursement applications in which the efﬁ cacy
assessment is limited to surrogate outcome data is increasing. Pressure to bring 
products to market quickly and facilitate access by patients to new treatments, as
well as the costs and time involved in conducting clinical endpoint trials, has led to
increasing reliance on these data. While substantial activity is focused on methodo-
logical, mainly statistical, approaches to the validation of surrogate outcomes, the
determination of the magnitude of absolute or comparative treatment beneﬁ t offered 
by new medicines must be made by regulatory and reimbursement decision makers 
even where validity has not been clearly demonstrated. GOALS: To highlight the 
need for a more coordinated approach to clinical trial design and the assessment
of outcome data by regulatory and reimbursement agencies with respect to reliance 
on surrogate outcomes. OUTCOMES ITEMS USED IN THE DECISION:
IMPLEMENTATION STRATEGY: In late 2007, the PBAC established a multi-
disciplinary working group which included representatives from the PBAC and its 
Economics Sub-Committee, and the Australian regulator (the Therapeutic Goods 
Administration), as well as external experts, and representatives of the pharmaceutical
industry with the objective of identifying recent developments, policy and method-
ological, with respect to surrogate outcome data. RESULTS: One of the more complex
issues encountered during the comparative effectiveness and comparative cost effec-
tiveness assessment of medicines is the determination of the incremental treatment
effect when the available evidence is limited to surrogate outcome data. Reimburse-
ment decision-makers attempting to determine incremental cost effectiveness must 
not only identify any qualitative difference in treatment effect, this must also be mea-
sured and valued for incorporation into cost effectiveness analysis. Where clinical 
beneﬁ t is only demonstrated against a surrogate endpoint and where the validity 
of that surrogate endpoint is uncertain, the relationship between a change in the
surrogate and a change in the ﬁ nal clinical endpoint will also be uncertain. Despite 
much analysis and deliberation the working group was unable to identify a deﬁ nitive 
strategy for evaluating a surrogate outcome data in the context of an economic 
evaluation, but acknowledged that the transformation of surrogates outcomes into
ﬁ nal outcomes is associated with signiﬁ cant and extensive uncertainty which can sub-
stantively impact on the capacity of decision makers to make robust determinations
of comparative cost effectiveness. This difﬁ culty and uncertainty could be reduced 
through greater, earlier and more systematic collaboration between regulators and
funders, and coordinated engagement with the developers of new products. Although
formal cooperation agreements exist between a number of regulatory agencies, formal 
relationships between regulators such as the EMEA and any of the European 
HTA/reimbursement agencies, such as the UK’s National Institute for Health and 
Clinical Excellence (NICE), for the joint identiﬁ cation, evaluation and validation of 
surrogate endpoints, and the determination of the signiﬁ cance accorded to them in
the regulatory and reimbursement decision-making process, do not appear to exist.
LESSONS LEARNED: Regulators evaluating medicines for marketing approval pro-
cesses are not the only decision makers who rely on the results of randomised trials. 
The commercial success of a new medicine is increasingly dependent on a successful 
reimbursement approval, and this often means signiﬁ cant public investment. Ideally
regulatory-reimbursement collaboration should occur in the design phase of clinical 
trials so that endpoints that are meaningful, measurable and relevant to both regula-
tors and funders are identiﬁ ed and utilised. Policy makers currently debating the 
establishment of a framework for comparative effectiveness research in the United 
States may also wish to engage in the debate around the identiﬁ cation, selection and 
validation of surrogate endpoints as this will be essential to the meaningful interpreta-
tion of these comparative analyses. Overall, the role of multiple decision makers in
the process from drug development to drug subsidy and the need for better coordina-
tion is a very important one.
CASE3
HEALTH SERVICES PHARMACEUTICAL COVERAGE FOR
COMMON DISEASES MAY BE CHALLENGED BY SIGNIFICANT 
RISE IN ONCOLOGY DRUG EXPENDITURE
Katzir I, Westerman-Landes J, Siegelmann-Danieli N, Kokia E, Lomnicky Y
Maccabi Healthcare Services, Tel Aviv, Israel
ORGANIZATION: Maccabi Healthcare Services. PROBLEM OR ISSUE 
ADDRESSED: Health Care Services face the challenges of accommodating modern 
therapies in the face of rising costs for newly developed drugs. Maccabi Health Services 
(MHS) is an leading Israeli health organization known for an early adoption of newly 
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